Background {#Sec1}
==========

Gliomas are the most frequent primary brain tumours in adults. According to WHO classification \[[@CR1]\], molecular parameters and histology enable grading of the tumour as low grade (grade 2) or high grade (grade 3 or anaplastic gliomas; and grade 4 or glioblastomas) with increasing aggressiveness \[[@CR2]\]. Major efforts have been made to identify relevant prognostic and predictive biomarkers in high grade gliomas including *IDH* (isocitrate dehydrogenase) mutations or ATRX (Alpha Thalassemia/mental Retardation syndrome X-linked) expression \[[@CR3], [@CR4]\]. Most alterations found in high grade gliomas target signalling pathways involved in invasion, signal transduction, cell-cycle control, DNA repair, angiogenesis or cell metabolism \[[@CR5], [@CR6]\].

The management of high grade gliomas includes maximal possible surgery because it reduces the symptoms from mass effect and probably improves survival. First line adjuvant therapy is based on systematic normofractionated radiotherapy (RT) (total dose of 60Gy; 5 fractions of 2Gy/week over 6 weeks), with daily temozolomide-based chemotherapy \[[@CR7], [@CR8]\]. Despite these treatments, median survival remains very low around 14 months. Early tumor relapses occur mostly within the high dose irradiated volume due to a high resistance of high grade glioma cells to RT \[[@CR9]\]. Treatment options for recurrent high grade glioma are limited and hypofractionated stereotactic RT (HFRT) is one option with limited efficacy \[[@CR10]--[@CR14]\]. HFRT using fraction doses of 5--8 Gy provides normal tissue protection by its steep dose gradient while still providing the radiobiological potential advantage of high fraction doses. The reduced overall treatment time is an advantage for patients with short life expectancy. Therefore, a better understanding of biological mechanisms involved in high grade gliomas radioresistance to HFRT is a major issue for future drug development in the field of radiosensitization.

Common preclinical models for exploring cancer resistance to RT and radiosensitizing drugs include cultured human tumor cell lines in monolayer, xenografts derived from the same human cell lines or derived from patient samples grown subcutaneously in immunodeficient mice and orthotopic models \[[@CR15], [@CR16]\]. Although cell line xenograft models present only murine stroma, and minimal intra-tumoral heterogeneity, they constitute valuable in vivo models with high rates of successful engraftment, allowing a three-dimensional tumor cell proliferation.

High-throughput screening approaches are largely used to characterize cell lines and tumors and identify predictive biomarkers of treatment response \[[@CR17]\]. The most currently used analyzed the RNA content (transcriptome) or DNA modification (genome) through dedicated microarrays or more recently high throughput sequencing. However in mammalian cells, a lot of regulatory modifications occur at post-transcriptional and translational levels and it is widely accepted that proteins amount and their modifications regulate cell signaling pathways that govern cell behavior, and their capacity to proliferate and escape from treatment \[[@CR18], [@CR19]\]. These differences could account for discrepancies sometimes reported between response to treatment in cell lines and results in vivo \[[@CR16], [@CR20]\]. However, despite the increasing interest for proteome, the methods to characterize it are still limited. In this study, we used reverse-phase protein array (RPPA), a technology using high-throughput antibody-based detection. It requires only a few μg of protein lysate and allows assessing protein expression and their main modification status in a highly quantitative manner \[[@CR19], [@CR21]\]. This technology can analyze hundreds of samples simultaneously on the same array and thus generate large datasets to identify potential diagnostic, prognostic, and predictive markers in human cancer \[[@CR22]\].

The aim of this study was to search for predictive biomarkers of radioresponse on nude mice engrafted with high grade glioma cell lines and patient-derived tumor samples irradiated with a HFRT regimen. We explored a selection of proteins and modifications related to 10 different signaling pathways potentially involved in radioresistance: DNA repair \[[@CR23]\], PI3K pathway \[[@CR24]\], apoptosis \[[@CR25]\], tyrosine kinase signaling \[[@CR26]\], stress signaling, cell cycle \[[@CR27]\], MAPK/ERK signaling, SAPK/JNK signaling \[[@CR28]\], NFκB signaling \[[@CR29]\] and adhesion/cytoskeleton \[[@CR30]\].

Methods {#Sec2}
=======

Cell culture {#Sec3}
------------

SF763, SF767, and U87MG human glioma cell lines (Table [1](#Tab1){ref-type="table"}) were given by Dr. C. Delmas (Centre Claudius Regaud, Toulouse, France). T98G, U118MG and CB193 cell lines (Table [1](#Tab1){ref-type="table"}) were kindly provided by G. Pennarun (CEA, Grenoble, France). All culture reagents were purchased from GIBCO (Invitrogen, Cergy-Pontoise, France). Cells were grown in DMEM (with 4500 mg/l glucose and L-glutamine) supplemented with Sodium Pyruvate 1%, Non-Essential Amino Acids 1%, Gentamicin 10 μg/ml and 10% Fetal Calf Serum in a humidified incubator containing 5% CO2 at 37 °C.Table 1Radiosensitivity of in vivo glioma modelsNameOriginXenograft originTreatmentNumber of miceMedian survival in daysSurvival enhancement after RT (%)*p*-value^a^Mean TGD in days (%)Quadrupling Time of RT vs NT *p*-value^b^CB193glioma grade IIICell lineNT942 \[37;46\]226\< 0.00166 ± 13 (351)\< 0.01RT695 \[88;140\]SF763glioblastomaCell lineNT1239 \[32;52\]226\< 0.0154 ± 15 (399)\< 0.001RT788 \[81;102\]SF767glioblastomaCell lineNT877 \[65;80\]168\< 0.00152 ± 7 (215)\< 0.001RT12129 \[101;140\]T98GglioblastomaCell lineNT820 \[16;23\]175\< 0.00115 ± 5 (259)\< 0.01RT835 \[33;37\]U87MGglioblastomaCell lineNT629 \[22;30\]134\< 0.00111 ± 1 (149)\< 0.01RT1039 \[37;41\]U118MGglioblastomaCell lineNT638 \[23;49\]1790.05926 ± 4 (278)\< 0.01RT968 \[51;79\]GBM-1-HAMglioblastomaPatient sampleNT1316 \[14;18\]319\< 0.00119 ± 4 (320)\< 0.001RT951 \[37;72\]GBM-14-CHAglioblastomaPatient sampleNT616 \[14;19\]250\< 0.0012 ± 1 (115)nsRT1040 \[28;44\]GBM-14-RAVglioblastomaPatient sampleNT629 \[24;38\]259\< 0.00137 ± 5 (386)\< 0.01RT1075 \[61;82\]ODA-17-GIRglioma grade IIIPatient sampleNT619 \[14;25\]405\< 0.00155 ± 3 (715)\< 0.01RT877 \[65;79\]ODA-4-GENglioma grade IIIPatient sampleNT626 \[20;28\]215\< 0.00133 ± 3 (462)\< 0.01RT856 \[51;63\]Medians were presented with inter-quartile range \[0.25; 0.75\] and means with standard-errors*ns* not significant, *NT* Not treated, *RT* Radiotherapy, *TGD* Tumor Growth Delay^a^Log-rank test^b^Mann Whitney Test

Xenograft models {#Sec4}
----------------

Xenografts derived from cell lines (CDX) were obtained by injecting 4 × 10^6^ cells of each cell line described above into the flank of adult female nude mice (Swiss nu/nu, Janvier, Le Genest Saint Isle, France). For patient derived xenograft (PDX), tumors are kept by successive grafting into scapular area or storage at −80 °C in fetal calf serum-free DMEM (Sigma-Aldrich, St Louis, MO, USA) for longer period. For each experiment, small fragments (50mm^3^) from scapular tumour were xenografted subcutaneously into the flank of anaesthetized nude mice (Swiss nu/nu, Janvier, Le Genest Saint Isle, France) aged 6--8 weeks. Xenografting was performed within 2 h following surgical resection, with fragments being kept in fetal calf serum-free DMEM (Sigma-Aldrich, St Louis, MO, USA) \[[@CR31]\].

The animals were housed in our animal facility for at least 1 week before starting the experiments. There were six animals per cage under controlled conditions of light and dark cycles (12 h: 12 h), relative humidity (55%), and temperature (21 °C). Food and tap water were available ad libitum. When subcutaneous tumors reached approximately 125 mm^3^, mice were separated into homogeneous groups (at least 6 mice per group) to receive different treatment protocols: no treatment (NT) or HFRT alone for 2 weeks (HFRT: 6 × 5 Gy each Monday, Wednesday, Friday). A ^137^Cs unit (0.5 Gy/min) with a shield designed to protect approximately two thirds of the animal's body was used to administer HFRT. Doses were controlled by thermoluminescence dosimetry. In all experiments, tumors were measured with a digital caliper every 2 to 3 days and any local skin toxicity was noted. Tumor volumes were calculated using the following formula: length × width × width/2. Mice were weighed every week and followed up for a maximum of 180 days. For ethical reasons, the animals were sacrificed when tumors reached 2000 mm3. The Local Committee on Ethics of Animal Experimentation approved all experiments.

Antibodies and validation {#Sec5}
-------------------------

The 65 antibodies used are listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1. We explored 39 total proteins, 26 phosphoproteins and then calculated 24 ratios of phosphoproteins on total proteins. These proteins and modifications were chosen as representative of 10 different signaling pathways potentially involved in radioresistance: DNA repair, PI3K pathway, apoptosis, tyrosine kinase signaling, stress signaling, cell cycle, MAPK/ERK signaling, SAPK/JNK signaling, NFκB signaling and adhesion/cytoskeleton (Additional file [1](#MOESM1){ref-type="media"}: Table S1). To ensure that our antibodies were of sufficient quality, we confirmed their specificity by Western blotting on a large panel of cell lines treated with ligands and inhibitors. Antibodies with only a single or dominant band on Western blotting were validated and used in RPPA.

Western blot {#Sec6}
------------

To ensure that our antibodies were of sufficient quality, we confirmed their specificity by Western blotting. For this, we used 14 cell lines from different origins, cultured in presence or absence of serum (inducing proliferation) and treated or not with bleocin (inducing DNA damage) or staurosporin (inducing apoptosis). 10 μg of lysate were run on precasted 4--15% polyacrylamide TGX gels (Bio-Rad). Transfer onto nitrocellulose was achieved using the Transblot Turbo (Bio-Rad). Membranes were blocked using TBS + 0.1% Tween +5% BSA. Primary antibodies were diluted in blocking solution and incubated overnight. Membranes were washed in TBS + 0.1% Tween and incubated for 1 h in secondary antibodies (Jackson ImmunoResearch), diluted in blocking solution. Membranes were washed and incubated with ECL (SuperSignal West Pico, Thermo Scientific) and signal was detected using a LAS3000 camera (Fuji). Antibodies with only a single or dominant band on Western blotting were validated and used in RPPA.

Preparation of protein lysates from tumor tissue {#Sec7}
------------------------------------------------

Tumors were mechanically disrupted in 1 mL (for 80 mg of sample) of Laemmli Buffer (50 mM Tris pH = 6.8, 2% SDS, 5% glycerol, 2 mM DTT, 2,5 mM EDTA, 2,5 mM EGTA, 2× Perbio Halt Phosphatase inhibitor cocktail, Roche Protease inhibitors complete MINI EDTA-free, 4 mM Sodium Orthovanadate, 20 mM Sodium Fluoride) using a Precellys (Bertin Technologies, Montigny le Bretonneux, France) with CK28 beads at 4 °C, 6000 rpm, 60s three times. Extracts were boiled for 10 min at +100 °C and spinned 15 min at 13000 rpm at 15 °C. The protein fraction was transfered to a new tube and spinned again at 13000 rpm, for 5 min, at 15 °C. The pellet was discarded and lysated were snapfrozen. Protein concentration was measured using the Reducing Agent Compatible BCA kit (Pierce, Rockford, IL, USA).

Reverse phase protein Array {#Sec8}
---------------------------

Proteins were analyzed with 6 replicates for subcutaneous xenograft models (2 different locations in three different tumors per model). Samples were printed onto nitrocellulose-covered slides (Schott Nexterion NC-C, Jena, Germany) with a dedicated arrayer (2470 Arrayer, Aushon Biosystems, Billerica, MA, USA). Five serial dilutions, ranging from 2 to 0.125 mg/ml, and four technical replicates per dilution were used for each sample. Detection was carried out with specific antibodies or without primary antibody (negative control), using an Autostainer Plus (Dako, Trappes, France). Briefly, slides were incubated with avidin, biotin, and peroxidase blocking reagents (Dako, Trappes, France) and then saturated with TBS supplemented with 0.1% Tween 20 and 5% BSA (TBST-BSA). The slides were then probed by overnight incubation at 4 °C with primary antibodies diluted in TBST-BSA. The arrays were washed in TBST and then probed with horseradish peroxidase-coupled secondary antibodies (Jackson ImmunoResearch, Newmarket, UK) diluted in TBST-BSA for 1 h at room temperature. The signal was amplified by incubating the slides with amplification reagent (Bio-Rad, Cressier, Switzerland) for 15 min at room temperature. The arrays were then washed with TBST, probed with Cy5-streptavidin (Jackson ImmunoResearch, Newmarket, UK) diluted in TBST-BSA for 1 h at room temperature, and washed again in TBST. Total protein staining was achieved by incubating the arrays for 15 min in 7% acetic acid and 10% methanol, rinsing twice in water, incubating for 10 min in Sypro Ruby (Invitrogen, Cergy-Pontoise, France), and rinsing again. The processed slides were dried by centrifugation and scanned with a GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA). Spot intensity was determined with MicroVigene software (VigeneTech Inc., Carlisle, MA, USA). Quantification of the data was achieved with NormaCurve \[[@CR32]\], which includes data normalization against negative control slides and Sypro Ruby slides.

Statistical analysis {#Sec9}
--------------------

Statistical analysis was performed using R v2.15.1 (<http://www.cran.r-project.org>). The tests were two-sided, with a Type I error set at α = 0.05. Continuous data were expressed according to sample size and to statistical distribution. So, medians were presented with inter-quartile range \[0.25; 0.75\] and means with standard-error. The study of relation between quantitative parameters was explored by Pearson or Spearman correlation coefficients r, according to statistical distribution (assumption of normality studied using Shapiro-Wilk test). To explore variations between PDX and CDX tumor growth before and after radiation, Mann-Whitney test were performed according to sample size and if assumptions of parametric test are not met (normality and homoscedasticity). Tumor growth delay (TGD) was calculated by subtracting the mean tumor volume quadrupling time of the control group from tumor volume quadrupling times of individual mice in each treatment group. The mean TGD was calculated for each treatment group from the individual measurements and was used to determine xenografts radioresponse. Survival curves were plotted according to the Kaplan--Meier method, and survival fraction of control and irradiated groups was compared using log-rank test analyses. *P*-value of less than or equal to 0.05 was considered to be a significant difference. Heatmaps were drawn using Gplots library.

Results {#Sec10}
=======

In vivo radiosensitivity determination {#Sec11}
--------------------------------------

CDX or PDX were generated to assess in vivo response to HFRT. Without irradiation, the 5 PDX had significantly faster tumor growth than the 6 CDX (mean tumor quadrupling time of 10 days vs 23 days, *p* \< 0.05) and lower survival (median survival of 22 days vs 43 days, *p* \< 0.05, Table [1](#Tab1){ref-type="table"}). However, PDX and CDX had similar response after irradiation as the difference of median survival (around 20 days) was conserved after irradiation (59 days vs 78 days, *p* = 0.41, See Additional file [2](#MOESM2){ref-type="media"}: Fig. S1). TGD measures the difference between the mean time required to attain a four-times increase of irradiated tumor volume as compared to non-irradiated controls (Fig. [1](#Fig1){ref-type="fig"}). TGD should not be highly sensitive to tumor growth speed. In most tumor models, HFRT temporarily blocks tumor growth, with a tumor growth arrest after the end treatment (10 days) that remains stable for up to 40 days (the best responder being ODA-17-GIR, GBM-14-RAV, CB193, SF767). The GBM-14-CHA did not show any growth arrest after HFRT. HFRT enhanced survival of all engrafted mice (fold increase of median survival ranged from 140 to 390%, Table [1](#Tab1){ref-type="table"}). Mean TGD and median survival were correlated (*p* = 0.005, *r* = 0.78). GBM-14-CHA had the lowest TGD and thus was considered as the most radioresistant xenograft while ODA-17-GIR had the highest TGD and thus was the most radiosensitive (Table [1](#Tab1){ref-type="table"}).Fig. 1In vivo glioma models tumor growth after radiotherapy. Xenografts derived from cell lines (CDX) were obtained by injecting grade III or glioblastoma (GBM) cells into the flank of nude mice. For patient derived xenograft (PDX), each tumour was xenografted subcutaneously into the scapular area after a maximal delay of 2 h after surgical resection. Representation of tumour growth kinetics in NT group (dotted-line, *n* ≥ 6) and in group treated with 6 × 5 Gy (solid line, *n* ≥ 6)

Protein biomarkers of radioresistance {#Sec12}
-------------------------------------

We used an RPPA approach to identify biomarkers of radioresponse in glioma subcutaneous xenografts (*n* = 11). A total of 89 protein markers: 39 total proteins, 26 phosphoproteins and 24 calculated ratios of phosphoproteins on total proteins were analyzed (See Additional file [1](#MOESM1){ref-type="media"}: Table S1). To take into account intrinsic variations, 6 different tumor samples were analyzed per model. We did not find significant variations between samples outlining little heterogeneity of biological replicates \[[@CR33]\].

Firstly, we compared protein profile of CDX and PDX using unsupervised hierarchical clustering of the RPPA data (See Additional file [3](#MOESM3){ref-type="media"}: Fig. S2). There was no clear difference between protein profiles of tumors issued from CDX or PDX grafting. Protein patterns were not dependent on the type of graft (CDX vs PDX), but rather vary between models. Indeed, no protein was found significantly differentially expressed between CDX and PDX models.

Then, we looked for proteins biomarkers of radioresponse in vivo. For this, we sought to explore the relationship between TGD and the 89 protein markers previously obtained by RPPA assay. Interestingly, the markers specific of in vivo resistance to radiotherapy were Phospho-EGFR (Tyr1173) on EGFR (*p* = 0.02, *r* = 0.69), Phospho-Chk1 (Ser280) on Chk1 (*p* = 0.02, *r* = 0.67) and the VCP (valosine-containing protein, *p* = 0.03, *r* = 0.63), which is a chaperone protein that regulates ubiquitin-dependent protein degradation. In vivo biomarkers were positively correlated to radioresistance with a high level being associated to more resistance (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Markers associated with response to irradiation. Identified biomarkers for in vivo response to irradiation. Protein level (arbitrary units) is plot together with Tumor Growth Delay(%). Data are presented by their mean ± standard error

Discussion {#Sec13}
==========

Despite encouraging preclinical results, and numerous clinical trials \[[@CR34]--[@CR37]\], only one targeted therapy has so far been approved for clinical use in combination with RT in head and neck cancer \[[@CR38]\] and none in high grade glioma treatment. Therefore, a better understanding of the mechanisms involved in RT resistance of a type of cancer (theranostic biomarkers) is necessary prior to proposing combined treatments with RT. Optimization of RT efficiency is one of the most promising approaches to increase patient survival notably high grade glioma. Stereotactic HFRT is appealing in the treatment of recurrent high grade glioma because of its ability to accurately deliver high doses of RT in a single or several fractions and to spare surrounding normal brain tissue \[[@CR10]--[@CR14]\]. Median survival in these series was between 7 and 13 months from time of salvage treatment with acceptable toxicity. However, despite recent developments in the spatial targeting of HFRT \[[@CR39], [@CR40]\], the inability to obtain long term control of diseases emphasizes the need to overcome tumor radioresistance with new agents that target molecular and cellular pathways underlying the mechanisms of such resistance. Here we aimed to look for predictive in vivo biomarkers of glioma radioresistance to HFRT in order to identify potential druggable targets. We used sub-cutaneous xenografts, rather than orthotopic in vivo model because subcutaneous xenograft models are very convenient to avoid radiation side effects and to monitor accurately tumor growth \[[@CR41], [@CR42]\]. Furthermore, we studied the response to a HFRT protocol currently used in high grade glioma reirradiation \[[@CR10], [@CR13]\] (6 fractions of 5 Gy over 2 weeks) that could not be ethically studied in orthopic xenografts due to its potential high level of toxicity in mice \[[@CR43]\]. One bias of our analysis might be that HFRT has been applied in previously unirradiated xenografts. Initial irradiation might affect tumor bed microenvironment such as blood vessels, and effects of re-irradiation with HFRT might be influenced by that. However, it is impossible and unethical to reproduce the conditions used in clinics in mice models both concerning initial total dose of radiation therapy (60Gy in 30 fractions) and the delay between initial irradiation and re-irradiation (\>6--12 months).

As RT cytotoxicity is mainly due to DNA damage, we explored the correlation between DNA repair enzymes status and survival to irradiation. Several studies suggested that overexpression/activation of H2AX, 53BP1 or P53 could be associated to radioresistance \[[@CR44], [@CR45]\] but none of this studies addressed the specific question of high grade glioma radioresistance to HFRT. Expression of most of proteins directly involved in DNA repair were not significantly different between sensitive and resistant xenografts. We did not find any correlation between the level of DNA-PK, a key player in NHEJ double-strand break repair, and radiosensitivity in xenografts. However, VCP, a potentially regulator of DNA-PK activity, was associated with in vivo radioresponse to HFRT. VCP is a chaperone protein that regulates ubiquitin-dependent protein degradation \[[@CR46]\]. VCP could play a dual role in regulation of DNA repair by controlling the proteasome-mediated degradation of DNA-PK \[[@CR47]\] and acting at the damage site where it is phosphorylated by DNA-PK \[[@CR48]\] and interacts with several DNA repair and cell cycle proteins \[[@CR49]--[@CR51]\].

Two other proteins, the epidermal growth factor receptor (EGFR) and the checkpoint kinase (CHK1) were associated with in vivo radioresistance to HFRT, and could thus be potential targets for radiosensitization. CHK1 plays an important role in the DNA damage response to radiation (including cell cycle control) and has been notably involved in the resistance of glioma stem like cells to ionizing radiation \[[@CR27], [@CR52]\]. The interest for CHK1 targeting in cancer area is underlined by the use of several compounds (CCT245737, LY2606368, Prexasertib) in ongoing clinical trials, though none of them explore the association with radiotherapy.

EGFR, which was highly correlated to tumor response in our study has been found overexpressed in about 40% of glioblastomas \[[@CR53]\] with approximately 50% of tumors with *EGFR* amplification carrying a specific EGFR mutant (EGFRvIII) \[[@CR26]\]. EGFR signaling (belonging to tyrosine kinase signaling) is involved in growth signaling, differentiation, adhesion, migration and survival of cancer cells \[[@CR54]\]. More recent studies highlighted a direct link between EGFR signaling and DNA repair. Thus targeting EGFR signaling could be a promising way to radiosensitize human glioma \[[@CR55], [@CR56]\]. Prados et al. reported outcomes of a phase 2 study of EGFR inhibitor erlotinib + Temozolomide during and after RT in patients with newly diagnosed glioblastoma \[[@CR34]\]. Median survival was 19.3 months vs 14.1 months in the historical cohorts. However, in a phase 1/2 study of EGFR inhibitor gefitinib during and after RT, Chakravarti et al. did not find any survival benefit with historical cohort \[[@CR57]\]. Further clinical investigations are needed. A phase 2 trial is actually ongoing (NCT02800486) and addresses the specific question of the combination of EGFR inhibitor cetuximab with stereotactic HFRT for the treatment of previously irradiated recurrent high grade glioma.

Conclusions {#Sec14}
===========

Our study is one of the first studies to address the specific question of protein biomarkers of resistance to HFRT in high grade gliomas. We found 3 biomarkers of particular interest: VCP, EGFR and CHK1. Several compounds targeting EGFR or CHK1 are already in clinical use and our study suggest that combining these compounds with stereotactic HFRT for recurrent high grade gliomas might be of particular interest.
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Additional file 1: Table S1.Antibodies used in RPPA assay. (XLSX 18 kb) Additional file 2: Fig. S1.In vivo glioma models survival after radiotherapy. Xenografts derived from cell lines (CDX) were obtained by injecting grade III or glioblastoma (GBM) cells into the flank of nude mice. For patient derived xenograft (PDX), each tumour was xenografted subcutaneously into the scapular area after a maximal delay of 2 h after surgical resection. Survival curves of NT group (dotted-line, *n* ≥ 6) and group treated with 6 × 5 Gy (solid line, *n* ≥ 6) were plotted according to the Kaplan--Meier method, and survival fraction of groups was compared using log-rank test. (TIFF 1691 kb) Additional file 3: Fig. S2.Heatmap of the RPPA data for CDX and PDX. Data obtained for 5 PDX (Green) and 6 CDX (Blue) were used (6 relicates) by unsupervised hierarchical clustering using Gplots library in R software. Expression for the 65 proteins or phosphor-proteins studied range from low (white) to high (black). (TIFF 2112 kb)
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